4basebio
Mark Godfrey currently serves as Financial Controller at 4basebio since March 2021. Previously, Mark held the position of Financial Director at FOGA for a brief period in early 2021. Prior to this, Mark was Financial Controller at Expedeon from January 2015 to September 2020, where responsibilities included managing finance operations for a leading life sciences company. Mark also worked as Financial Controller at Toad Hall Nursery Group from March 2013 to January 2015, overseeing financial operations for a chain of nurseries. Earlier career experience includes roles at PA Consulting Group, progressing from Finance Assistant to US Assistant Financial Controller while pursuing CIMA qualifications. Mark is CIMA qualified and holds a Bachelor of Science in Accounting from the University of Hull.
This person is not in any teams
4basebio
4basebio is enabling next generation cell and gene therapies and vaccines with its technologies and solutions. We are able to design, manufacture and supply application-specific synthetic DNA or mRNA as well as targeted non-viral vectors for the delivery of nucleic acid payloads. Our novel synthetic DNA technology offers unique customisation potential, rapid turn-around times, and improved safety profiles, addressing the current limitations of plasmids and other DNA technologies. We currently offer four DNA construct types, each ideally suited for use in viral and non-viral vector applications, genome editing, vaccines and therapeutics, and DNA vaccine applications, respectively. Our proprietary non-viral delivery system, Hermes™, is a nanoparticle vector that can be customised to target cells or tissues of interest for a range of applications. This combines the safety and efficiency of lipid-based nanoparticles (LNPs) with the specificity of a targeting system, addressing the shortcoming associated with both viral vectors and non-targeted LNPs.